

### **REMARKS/ARGUMENTS**

Claims 4-5, 9, 12-18 are pending in this application. Claims 2-3, 6-8 and 10-11 have been canceled.

An election has been requested to the subject matter of:

Group I, claim(s) 2-3, 6-8 and 10-11, drawn to a pharmaceutical composition for use in the treatment of abnormally increased bone turnover or resorption comprising a rapamycin derivative.

Group II, claim(s), 4-5, 9 and 12-18, drawn to a method of treating a disease/condition comprising administering a rapamycin derivative.


In response to the restriction requirement, Applicants elect the invention of Group II.

With respect to the species, Applicants elect the rapamycin derivative 40-O-(2-hydroxyethyl)-rapamycin which is supported in the examples.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Date: April 4, 2008